19. Correlation between the combined PGA and BSA scale and PASI score in assessing the severity of plaque psoriasis
Main Article Content
Abstract
The study was conducted on 402 patients with plaque psoriasis at the National Hospital of Dermatology and Venereology from November 2024 to May 2025. Patient history and medical history were taken, and clinical examination and severity assessment were performed using various scales. The correlation between the combined PGA × BSA score and the PASI index was then analyzed. The results showed a robust correlation between the PASI and the combined PGA × BSA score, with strong to moderate correlations for BSA and PGA individually, as indicated on the scatter plot. In patients with large lesion areas (BSA ≥ 10%), a strong correlation was observed between PASI and PGA × BSA, with a Spearman coefficient of 0.881 and an ICC of 0.932, indicating a statistically significant difference (p < 0.05). Meanwhile, in patients with small to moderate lesion areas (BSA < 10%), the Spearman correlation coefficient between PASI and PGA × BSA was 0.657, along with an ICC of 0.546, indicating only a moderate correlation, with statistically significant difference (p < 0.05).
Article Details
Keywords
BSA, disease severity, PASI, PGA, PGA × BSA, plaque psoriasis
References
2. Trần Hậu Khang. Bệnh vảy nến. Bệnh Học Da Liễu. (Sách đào tạo sau đại học). Tập 1, Nhà Xuất Bản Y Học, 2014, 91-99.
3. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007; 25(6): 535-546. doi:10.1016/j.clindermatol.2007.08.007.
4. Lebwohl M. Psoriasis. Lancet. 2003; 361(9364): 1197-1204. doi:10.1016/S0140-6736(03)12954-6.
5. Armstrong AW, Puig L, Joshi A, et al. Validation of the PGAxBSA tool for assessing psoriasis severity in clinical practice. J Am Acad Dermatol. 2020; 82(3): 693-699. doi:10.1016/j.jaad.2019.08.001.
6. American Academy of Dermatology. Guidelines of care for the management of psoriasis with systemic therapies. Published 2023. Accessed August 5, 2025. https://www.aad.org/member/clinical-quality/guidelines/psoriasis.
7. Langley RGB, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2005; 51(4): 563-569. doi:10.1016/j.jaad.2004.09.006.
8. Lebwohl MG, Armstrong AW, Langley RG, et al. A Simplified Psoriasis Severity Measure: PGAxBSA Outperforms PASI in Mild Disease. Br J Dermatol. 2019; 180(2): 282-287. doi:10.1111/bjd.17200.
9. Walsh JA, Strober BE, Armstrong AW, et al. Validation of the PGAxBSA Tool for Assessing Psoriasis Severity in Clinical Practice. J Am Acad Dermatol. 2017; 76(4): 654-659. doi:10.1016/j.jaad.2016.10.042.
10. Armstrong AW, Puig L, Joshi A, et al. Comparison of Physician Global Assessment and Psoriasis Area and Severity Index as measures of psoriasis severity in clinical practice. J Am Acad Dermatol. 2020; 82(2): 369-375. doi:10.1016/j.jaad.2019.05.078.
11. Garg A, Lavian J, Lin G, et al. Measuring the severity of psoriasis through composite scoring: the evolution of physician and patient-reported assessments. J Psoriasis Psoriatic Arthritis. 2020; 5(1): 26-35. doi:10.1177/2475530320910828.
12. Wu JJ, Feldman SR, Rastogi S, et al. Comparison of the Physician Global Assessment and Psoriasis Area and Severity Index in patients with moderate to severe psoriasis. J Drugs Dermatol. 2018; 17(4): 407-412.
13. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058